Fundraising Fox

Satsuma Pharmaceuticals

South San Francisco, US · Founded 2016 · Delaware corporation · 3 known investors

Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101). The company's SMART (Simple MucoAdhesive Release Technology) drug-delivery platform aims to address efficacy and administration limitations of existing migraine treatment formulations.

BiotechHealthtechMedical Devices

Founders & leadership

Satsuma Pharmaceuticals was founded in 2016 by John Kollins.

JK
John KollinsFounder
TI
Tadayoshi IwashimaExecutive
TB
Thomas B. KingPresident and Board Director
RJRob Janosky
Rob JanoskyChief Commercial Officer
TO
Tom O'NeilChief Financial Officer
DP
David PrichardChief Operating Officer
KN
Koji NakajimaHead of Corporate Strategy

Board

HLHeath Lukatch
Heath LukatchBoard directorCo-Founder and Managing Partner at Red Tree Venture
MR
Michael RiebeBoard director
RS
Rajeev ShahBoard director
TK
Thomas KingBoard director

Investors · 3

OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Vivo CapitalPalo Alto · $10M – $50M
Red Tree VenturereportedSan Diegovia Heath Lukatch · board

Reported raises · per SEC filings

Form D private placements

$12.1M disclosed across 1 round · 2016

▶$12.1MraisedFeb 2018 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Heath LukatchDirector
  • John KollinsExecutive Officer, Director
  • Michael RiebeDirector
  • Rajeev ShahDirector
  • Tadayoshi IwashimaExecutive Officer
  • Thomas KingDirector
Offering amount
$12.3M
Amount sold
$12.1M
Minimum investment
$1
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape5 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.

Companies competing with Satsuma Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Ratefinance.yahoo.com · Mar 2023Satsuma raises $62 million for nasal drug delivery tech - Drug Delivery Businessdrugdeliverybusiness.com · Apr 2019Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financingprnewswire.com · Apr 2019

Frequently asked questions

What does Satsuma Pharmaceuticals do?
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101). The company's SMART (Simple MucoAdhesive Release Technology) drug-delivery platform aims to address efficacy and administration limitations of existing migraine treatment formulations.
Who founded Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals was founded by John Kollins in 2016.
Who are Satsuma Pharmaceuticals's investors?
Satsuma Pharmaceuticals's investors include OUP (Osage University Partners), Vivo Capital, Red Tree Venture.
How much funding has Satsuma Pharmaceuticals raised?
Satsuma Pharmaceuticals has disclosed $12.1M raised across 1 round.
Where is Satsuma Pharmaceuticals headquartered?
Satsuma Pharmaceuticals is headquartered in South San Francisco, US.